Sharemaestro Newsreel

Femasys Inc expected to post a loss of $1.30 a share - Earnings Preview

Femasys Inc is projected to report an earnings loss of $1.30 per share. This information is provided as an earnings preview from Refinitiv, indicating upcoming financial results for the company.

Interim CFO exit at Baxter International (NYSE: BAX) set for Sept 15

Baxter International announced that Interim Chief Financial Officer Anita Zielinski will resign effective September 15, 2026, to join another company. Her resignation, communicated on July 31, 2026, is not due to any disagreements with management or the board regarding operations, policies, financial disclosures, or …

Countdown to Becton Dickinson (BDX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Janus Henderson Group PLC Sells 53,900 Shares of Envista Holdings Corporation $NVST

Janus Henderson Group PLC reduced its stake in Envista Holdings Corporation (NYSE:NVST) by 11.3% in the first quarter, selling 53,900 shares, but still holds 421,915 shares valued at approximately $10.7 million. Envista recently saw a 2.1% increase in its stock price to $27.94, following …

AptarGroup (ATR) Segment President Hedi Tlili Sells 8,854 Shares

Hedi Tlili, Segment President of AptarGroup Inc (ATR), sold 8,854 shares of the company for approximately $1.2 million, retaining 15,379 shares. This transaction highlights a trend of insider selling at AptarGroup, with no insider buys and 11 sells over the past year. Despite this, …

ResMed Inc (RMD) Stock Up 3.7% and Still Undervalued -- GF Score: 90/100

ResMed Inc (RMD) saw its stock price increase by 3.7% to $223.14, and GuruFocus's GF Value™ assessment indicates it is currently undervalued with a fair value of $274.67. The company boasts a strong GF Score™ of 90/100, driven by excellent profitability and growth, though …

497,793,652 Class A Common Stock of Medline Inc. are subject to a Lock-Up Agreement Ending on 5-AUG-2026.

Approximately 497.8 million Class A Common Stock of Medline Inc. are under a lock-up agreement that concludes on August 5, 2026. This agreement, spanning 76 days from May 21, 2026, restricts officers, directors, principal stockholders, and pre-IPO investors from selling or hedging their shares …

L1 Capital reports Anteris Technologies disposal worth $4.25 million

L1 Capital, a 10% owner of Anteris Technologies Global, reported selling shares worth a total of $4.25 million in two separate transactions. On July 31, they sold 48,711 shares at $8.15, and on August 3, they sold 475,693 shares at $8.1. Following these disposals, …

Azenta, Inc. (AZTA) SVP acquires 335 shares via 2017 stock purchase plan

Ephraim Starr, SVP, General Counsel & Secretary of Azenta, Inc. (AZTA), purchased 335 shares of common stock on July 31, 2026, at $24.1676 per share through the company's 2017 Employee Stock Purchase Plan. This transaction, which was exempt from Section 16(b), increased his direct …

LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates

LeMaitre Vascular (LMAT) reported Q2 earnings of $0.74 per share, falling short of the Zacks Consensus Estimate of $0.81, though it was an increase from $0.60 a year ago. The company's revenues of $70.38 million also missed expectations, despite being higher than the $64.23 …

STAAR Surgical Reports More Than 4M Lenses Sold as CEO Changes

STAAR Surgical announced the appointment of Warren Foust as President and Chief Executive Officer, effective August 4, 2026, following an extensive global search. Foust, who previously served as Interim Co-CEO and President & Chief Operating Officer, will focus on revenue growth, profit expansion, and …

LeMaitre Vascular (NASDAQ:LMAT) Issues Q3 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) has lowered its third-quarter 2026 earnings guidance, projecting EPS of $0.660–$0.710 and revenue of $66.3–$68.3 million, both below analyst consensus. The company also updated its full-year 2026 EPS guidance to $2.840–$2.940. Despite the lowered outlook, analyst sentiment remains "Moderate Buy" with …

Stevanato Group SpA Revenue Breakdown – MUN:87N

Stevanato Group SpA (MUN:87N) reported a total revenue of €1.19 billion last year. The majority of this revenue, €997.60 million, came from its Biopharmaceutical and Diagnostic Solutions segment. EMEA was the largest contributing region, generating €663.30 million.

STAAR Surgical names Warren Foust CEO, Andrews to EVP and CFO

STAAR Surgical Company has appointed Warren Foust as President and CEO, and a new member of its Board of Directors, effective immediately. Deborah Andrews, who served as Interim Co-CEO alongside Foust, will now serve as Executive Vice President while continuing her role as Chief …

How Investors Are Reacting To LeMaitre Vascular (LMAT) Slower Projected Revenue Growth And Mixed Earnings Track Record

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group reported an 8% increase in revenue for the second quarter of fiscal 2026, reaching €302.0 million, primarily driven by its Biopharmaceutical and Diagnostic Solutions Segment. The company also updated its full-year 2026 guidance, expecting revenue between €1.260 billion and €1.280 billion, and …

Earnings call transcript: LeMaitre Vascular slips on Q2 2026 miss, cuts outlook

LeMaitre Vascular reported a Q2 2026 earnings and revenue miss, leading to a significant after-hours stock drop. Despite strong year-over-year growth and margin expansion, the company cut its full-year organic revenue growth outlook due to foreign exchange pressures, Middle East shipping delays, and cardiac …

Stronger Q2 Results, Guidance Hike, Buybacks Might Change The Case For Investing In West (WST)

West Pharmaceutical Services (WST) reported strong Q2 results with increased sales and net income, alongside raising its full-year 2026 revenue outlook and completing significant share repurchases. The company's upgraded organic revenue guidance, driven by biologics and biosimilars, reinforces its growth-focused investment thesis. While potential …

Earnings Flash (AZTA) Azenta, Inc. Posts Q3 Adjusted EPS $0.16 per Share

Azenta, Inc. (AZTA) announced its Q3 adjusted EPS of $0.16 per share, surpassing FactSet's estimate of $0.11. The company also reported Q3 revenue of $161.2 million, exceeding FactSet's estimate of $149.3 million. This financial update indicates a stronger performance than anticipated by analysts for …

STAAR Surgical to discuss vision correction business Aug. 12

STAAR Surgical (NASDAQ: STAA) announced it will release its second-quarter 2026 financial results and a shareholder letter on August 12, 2026, after market close. The company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial performance, operational …

Avantor (NYSE: AVTR) CAO has 1,385 shares withheld for taxes

Avantor, Inc.'s SVP & Chief Accounting Officer, Steven W. Eck, had 1,385 shares of common stock withheld on July 31, 2026, to cover tax obligations related to the vesting of Restricted Stock Units (RSUs). The shares were valued at $13.78 each. Following this transaction, …

Pulse Biosciences Inc expected to post a loss of 36 cents a share - Earnings Preview

Pulse Biosciences Inc (PLSE) is expected to report a loss of 36 cents per share, according to this earnings preview. The article from Reuters indicates this forecast without providing further details on the company's financial performance or future outlook.

Craftech Holdco acquired Balda C. Brewer, Inc. from Stevanato Group S.p.A..

Craftech Holdco successfully acquired Balda C. Brewer, Inc. from Stevanato Group S.p.A. on June 30, 2026. This transaction involved Stevanato Group S.p.A., which is listed on the NYSE under the ticker STVN. The news was published on August 4, 2026, at 5:23 pm EDT.

ResMed Inc. stock rises Tuesday, outperforms market

Shares of ResMed Inc. (RMD) rose 3.69% on Tuesday, closing at $223.14. This performance outpaced the broader market, with the S&P 500 Index (SPX) gaining 1.79% and the Dow Jones Industrial Average (DJIA) rising 1.71%. This marks the third consecutive day of gains for …

Stevanato Group (NYSE: STVN) grows H1 revenue, records disposal loss

Azenta reports Q3 fiscal 2026: Revenue $161M, Adjusted EBITDA $18.5M, Non-GAAP EPS $0.16

Azenta (AZTA) reported its fiscal Q3 2026 results with revenue of $161.2 million and non-GAAP diluted EPS of $0.16. The company achieved an adjusted EBITDA of $18.5 million, representing an 11.4% margin, and noted 9% organic revenue growth year over year. Azenta also reiterated …

Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.

Azenta, Inc. reported its third-quarter financial results for fiscal year 2026, exceeding expectations with continued strength in recurring revenue and a modest improvement in Multiomics in North America. The company's revenue from continuing operations was $161 million, an increase of 12% year-over-year, and it …

Stevanato Group (NYSE: STVN) grows Q2 sales 8% and updates 2026 view

Stevanato Group (NYSE: STVN) announced an 8% increase in Q2 2026 sales, primarily driven by a 9% rise in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and strong demand for High-Value Solutions (HVS), which grew 16%. The company also updated its full-year 2026 guidance, …

Proposed MMSI (MMSI) insider stock sale disclosed in Form 144 filing

A Form 144 filing indicates a proposed sale of up to 21,449 shares of Merit Medical Systems Inc. (MMSI) common stock by an affiliate. The shares, consisting of Performance Shares and Restricted Stock granted in 2025 and 2026, are expected to be sold on …

Kestra Medical Technologies (NASDAQ: KMTS) insider files to sell 3,580 shares

A Form 144 SEC filing indicates that an insider at Kestra Medical Technologies (NASDAQ: KMTS) plans to sell 3,580 shares of common stock through Merrill Lynch on August 4, 2026. This proposed sale follows the vesting of restricted stock unit awards granted as equity …

Stevanato Group (NYSE: STVN) grows Q2 revenue and sells Balda subsidiary

LeMaitre says Artegraft is now approved in 56 countries

LeMaitre (NASDAQ: LMAT) reported strong Q2 2026 financial results with net sales up 10% year-over-year to $70.4 million and diluted EPS up 23% to $0.74. A key growth driver was Artegraft, whose sales increased by 34%, now representing 21% of total sales and approved …

Envista earnings in focus: Can dental tech firm sustain momentum? By Investing.com

Envista Holdings Corp. is set to report its second-quarter results, with analysts expecting 34 cents per share on $716.6 million in revenue, reflecting year-over-year growth. Investors will be closely watching margin trajectory, segment performance, and competitive positioning, especially given the increased consolidation in the …

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Exploring a 14.61% Potential Upside in the Healthcare Sector

LeMaitre Vascular, Inc. (LMAT) is a significant player in the healthcare sector, specifically in medical instruments for vascular surgery, with a market capitalization of $2.37 billion. The company shows strong financial health with 11.20% revenue growth, a 16.55% return on equity, and a forward …

LeMaitre Vascular earnings on deck as margin gains test continues

LeMaitre Vascular is set to announce its second-quarter earnings, with investors closely watching its ability to maintain significant margin expansion and accelerate profit growth. Analysts anticipate earnings of $0.81 per share on revenue of $71.5 million, reflecting substantial year-over-year growth. The company's premium valuation …

Microbot Medical (MBOT) Expected to Announce Quarterly Earnings on Tuesday

Microbot Medical (MBOT) is anticipated to report its Q2 2026 earnings before the market opens on Tuesday, August 11th. Analysts project a loss of $0.08 per share on revenue of $0.333 million, with an investor call scheduled for August 13th. The company's previous quarter …